Global Subcutaneous Injector Market Overview:
Subcutaneous injectors are bolus injector that utilized for medications and administer drugs. It also employed with several vaccines and medication such as insulin, goserelin and diacetylmorphine. Subcutaneous injectors market is expected to mark significant growth over forecasted period due to communicable diseases and technological advancement. There has been significant rise in number of people affected with neonatal deaths, infant deaths and neurological impairment with figure stood up to 70%, 36% and 25-50% in United States alone, so the application of Subcutaneous injectors market is expected to growing. The major companies are adding more proven technologies systematically and strategically in Asia-Pacific countries as these countries are focused on curing prevalence of chronic diseases. According to AMA, the Global Subcutaneous Injector market is expected to see growth rate of 14.8% and may see market size of USD24376.0 Million by 2024.
- Growing Prevalence of Chronic Diseases has Boosted the Subcutaneous Injector Market.
- Rapid Demand of Self-Injection Device Fuelled up the Market.
- Collaboration and Tie Up Of Leading Players
- Innovation and Technology in the Field of Subcutaneous Injector Market.
- High Cost Associated With Subcutaneous Injector Device.
- Lack of Awareness Hampers the Subcutaneous Injector Market.
- Proliferation of Vaccinations and Biosimilar Leads to Grow the Subcutaneous Injector Market.
- Upsurge Demand of Subcutaneous Injector in Emerging Market.
- Limitation Due to Alternative Mode of Drug Delivery are Anticipated to Challenge the Market.
- Government Rules And Regulations Fluctuate The Market.
In subcutaneous injector market, it has been observed that most of the companies are upgrading or introducing different techniques such as patient convenience, potential for self-administration, better therapy adherence and reduced healthcare costs, the concept is steadily gaining traction within the healthcare industry.
Some of the key players profiled in the report are Antares Pharma Inc. (United States), Endo International PLC. (Ireland), PharmaJet Inc. (United States), Bioject Medical Technologies Inc. (United States), Medical International Technology Inc. (Canada), National Medical Products Inc. (United States) and Valeritas Holdings Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like European Pharma Group Ltd. (The Netherlands), PenJet Corporation (The Netherlands) and Crossject SA (France). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Subcutaneous Injector market by 2024. Considering Market by Medication, the sub-segment i.e. Liquid will boost the Subcutaneous Injector market. Considering Market by Usability, the sub-segment i.e. Reusable will boost the Subcutaneous Injector market. Considering Market by End User, the sub-segment i.e. Hospital will boost the Subcutaneous Injector market.
“In February 2018, AMAG Pharmaceuticals, Inc. announced that U.S. Food and Drug Administration (FDA) approved the Makena subcutaneous auto-injector which is beneficial in providing treatment to reduce the risk of preterm birth in women pregnant with one baby. It also offers new administration option for patients and providers and contains a shorter, thinner non-visible needle compared to the intramuscular (IM) Makena injection.”
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Subcutaneous Injector market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Subcutaneous Injector market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Subcutaneous Injector Manufacturers, Subcutaneous Injector Traders, End-Use Market Participants of Different Segments of Subcutaneous Injector, Government and Research Organizations, R&D Institutions and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.